X0203 3 2010-10-21 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001257444 ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280234 ALTA BIOPHARMA MANAGEMENT III LLC ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280265 ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001280238 ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC ONE EMBARCADERO CENTER SUITE 3700 CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198323 DELEAGE JEAN ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001211840 HURWITZ EDWARD ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 0001198332 PENHOET EDWARD ONE EMBARCADERO CENTER SUITE 3700 SAN FRANCISCO CA 94111 0 0 1 0 Series A Convertible Preferred Stock Common Stock 1086336 D Series A Convertible Preferred Stock Common Stock 72957 D Series A Convertible Preferred Stock Common Stock 26771 D Series B Convertible Preferred Stock Common Stock 379545 D Series B Convertible Preferred Stock Common Stock 25490 D Series B Convertible Preferred Stock Common Stock 9353 D Senior Subordinated Convertible Promissory Notes 7.60 2011-12-31 Common Stock 700050 D Senior Subordinated Convertible Promissory Notes 7.60 2011-12-31 Common Stock 47010 D Senior Subordinated Convertible Promissory Notes 7.60 2011-12-31 Common Stock 17250 D The Series A Convertible Preferred Shares (the "Series A Shares") were issued on December 16, 2005 and the Series B Convertible Preferred Shares (the "Series B Shares") were issued on November 13, 2007. Each of the Series A shares and Series B shares are convertible, in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation, at any time after the issuance of such share, at the holder's election. The Series A Shares and the Series B Shares will convert automatically into Common Stock, without the payment of additional consideration, upon the closing of the Issuer's initial public offering and do not have an expiration date. The Series A Shares will convert on a 1-for-0.38701117412 basis and the Series B Shares will convert on a 1-for-0.61027657931 basis. These securities are beneficially owned by Alta BioPharma Partners III, L.P. ("ABPIII"). Alta BioPharma Management III, LLC ("ABMIII") is the general partner of ABPIII and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG"). Jean Deleage, Farah Champsi, Edward Penhoet and Edward Hurwitz are the directors of ABMIII and managers of Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII"). Alison Kiley, a director of the Issuer, is a member of ABMIII and may be deemed to share investment power over the securities of the Issuer held by ABPIII, ABPIIIKG and AEBPIII with the directors of ABMIII and managers of AEBPIII. Mr. Deleage, Ms. Champsi, Mr. Penhoet, Mr. Hurwitz, and Ms. Kiley disclaim beneficial ownership of such securities except to the extent of his or her pecuniary interest therein These securities are beneficially owned by ABPIIIKG. These securities are beneficially owned by AEBPIII. Reflects $4,823,353.04 aggregate principal amount of the Issuer's senior subordinated convertible promissory notes (the "Convertible Notes") held by ABPIII, dated September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010, and October 1, 2010. The outstanding principal and accrued and unpaid interest on these Convertible Notes are automatically convertible into shares of common stock upon the closing of the Issuer's initial public offering. The outstanding principal and accrued and unpaid interest on the Convertible Notes shall automatically be converted into shares of common stock upon the closing of the Issuer's initial public offering at $7.60 per share, 80% of the initial public offering price per share. Reflects $323,930.29 aggregate principal amount of Convertible Notes held by ABPIIIKG, dated September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010, and October 1, 2010. The outstanding principal and accrued and unpaid interest on these Convertible Notes are automatically convertible into shares of common stock upon the closing of the Issuer's initial public offering. Reflects $118,867.78 aggregate principal amount of Convertible Notes held by AEBPIII, dated September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010, and October 1, 2010. The outstanding principal and accrued and unpaid interest on these Convertible Notes are automatically convertible into shares of common stock upon the closing of the Issuer's initial public offering. By Alta BioPharma Management III, LLC /s/ Jean Deleage, Director 2010-10-21 /s/ Jean Deleage, Director 2010-10-21 By Alta BioPharma Management III, LLC, /s/ Jean Deleage, Director 2010-10-21 /s/ Jean Deleage, Manager 2010-10-21 /s/ Farah Champsi 2010-10-21 /s/ Jean Deleage 2010-10-21 /s/ Edward Hurwitz 2010-10-21 /s/ Edward Penhoet 2010-10-21